The chart below shows how ZIMV performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ZIMV sees a +6.81% change in stock price 10 days leading up to the earnings, and a +4.64% change 10 days following the report. On the earnings day itself, the stock moves by -3.43%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Q3 Revenue Performance: 1. Strong Revenue Performance: ZimVie reported third-party net sales of $103.2 million for Q3 2024, with U.S. sales growing by 1.6% when excluding the impact of oral scanner sales.
Gross Margin Improvement: 2. Improved Gross Margin: The adjusted cost of products sold decreased by 60 basis points sequentially from the second quarter of 2024, contributing to a 12.7% adjusted EBITDA margin, up from 11.6% in the prior year period.
Debt Management Strategy: 3. Debt Reduction: The company paid down $15 million in debt during the quarter, resulting in a net debt balance of approximately $153 million, which reflects a strong commitment to improving its financial position.
Digital Portfolio Expansion: 4. Digital Portfolio Growth: The complete digital portfolio, excluding iTero scanner sales, grew over 10% in Q3 2024, with the RealGUIDE software experiencing over 30% growth year-over-year.
Future Growth Confidence: 5. Positive Outlook for Future Growth: ZimVie narrowed its full-year revenue guidance to $450 million to $455 million, indicating confidence in continued growth and recovery in the North American market.
Negative
Third-Party Net Sales Decline: Total third-party net sales for Q3 2024 were $103.2 million, a decrease of 2% in reported rates and a decline of 2.2% in constant currency versus the prior year period.
International Sales Decline: Outside of the U.S., third-party net sales of $37.9 million decreased 6% on a reported basis and 6.6% in constant currency, primarily driven by the timing of orders in Japan and Italy and a slower market in Spain.
Rising R&D Expenses: Adjusted research and development expense increased to $6.6 million or 6.4% of sales compared to $5.3 million or 5% of sales in the prior year, indicating rising costs without corresponding revenue growth.
Revenue Guidance Adjustment: Full year revenue guidance was narrowed to $450 million to $455 million from a previous range of $450 million to $460 million, reflecting a lack of confidence in achieving higher sales.
Share-Based Compensation Expense: The company expects share-based compensation expense to be approximately $6.3 million for the full year 2024, indicating ongoing financial strain.
ZimVie Inc. (ZIMV) Q3 2024 Earnings Call Transcript
ZIMV.O
-1.26%